Entomed and NAEJA Pharma join in screening program

French drug discovery company Entomed SA and Canada-based NAEJAPharmaceuticals have entered into a screening agreement. Under the terms of the deal, both companies will share the intellectual property arising from any discoveries made, and each will have an option to progress the development compounds within their respective fields of interest.

According to this two-way accord, aimed at identifying new lead in infectious diseases and cancer, NAEJA will have access to the French firm's Entometheque library for screening beta lactamase inhibitors, while Entomed will be able to investigate the Canadian group's proprietary compounds library for anti-proliferative activities.